Drug Database · Clinicians

Amino acids + Electrolytes + Glucose + Lipid emulsion

Brands (5) Combiflex Lipid Central, Combiflex Lipid Peri, Combiflex MCT Peri…Show all

Part of: Parenteral nutrition products (Drug Index, by product type)

Parenteral nutrition PH FDA category
Fixed-dose combination.

Rx · Prescription drug5 PH products PN kidney notes reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Parenteral nutrition: kidney notes

Brand-specific kidney notes for the parenteral nutrition products filed under this generic: composition from the manufacturer SmPC or package insert, its kidney-related text, and how the product fits the guideline. Sources are listed under References.

Brands: SmofKabiven Central · SmofKabiven Peripheral

Kidney notes: SmofKabiven Central

SmofKabiven Central (Fresenius Kabi AB) is a three-chamber bag of amino acids with electrolytes, glucose and SMOFlipid (soybean oil, medium-chain triglycerides, olive oil and fish oil) for central-vein parenteral nutrition. The Philippine registration is the 1970 ml bag. It is a standard formula containing potassium, phosphate and magnesium.

Composition

Per presentation1970 ml bagper 1000 ml
Amino acids (g)10051
Nitrogen (g)168
Lipid (g)7538
Glucose (g)250127
Energy, total, approx. (kcal)22001100
Energy, non-protein, approx. (kcal)1800900
Sodium (mmol)8041
Potassium (mmol)6030
Magnesium (mmol)105.1
Calcium (mmol)52.5
Phosphate (mmol)2513
Zinc (mmol)0.080.04
Sulfate (mmol)105.1
Chloride (mmol)7036
Acetate (mmol)209106
  • Osmolality approximately 1800 mosmol/kg water; osmolarity approximately 1500 mosmol/l (SmPC section 3).
  • Composition from the Irish (EU) SmPC; the Philippine package insert was not available to compare.

Composition from the cited manufacturer SmPC/package insert; values independently re-checked November 17, 2026.

Dose and rate limits

  • Infusion rate should not exceed 2.0 ml/kg body weight per hour; maximum daily dose 35 ml/kg body weight per day (SmPC 4.2).

Kidney notes

  • Contraindicated in "severe renal insufficiency without access to hemofiltration or dialysis" and with pathologically elevated serum levels of any of the included electrolytes (SmPC 4.3).
  • In patients with renal insufficiency, phosphate and potassium intake should be carefully controlled to prevent hyperphosphatemia and hyperkalemia (SmPC 4.4).
  • Give with caution in impaired lipid metabolism, which may occur in renal failure, and to patients with a tendency towards electrolyte retention; correct fluid and electrolyte disturbances before starting (SmPC 4.4).
  • The lipid emulsion (SMOFlipid) contains fish oil; see ESPEN Recommendation 27 on omega-3-enriched PN in kidney disease.

How it fits the ESPEN 2021 kidney nutrition guideline

  • ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
  • ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)
  • ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
  • ESPEN 2021 Recommendation 26: "In selected patients with electrolyte and fluid imbalances, concentrated “renal” EN or PN formulas with lower electrolyte content may be preferred over standard formulas." Grade of recommendation GPP – Strong consensus (95.7% agreement). (GPP, good practice point.)
  • ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 29: "Serum glucose levels shall be maintained between 140–180 mg/dl in hospitalized patients with AKI, AKI on CKD, or CKD with KF." Grade of recommendation A – Strong consensus (95.5% agreement). Recommendation 30: "Tight glucose control (80–110 mg/dl) shall not be pursued because of the increased risk of hypoglycemia." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 14: "For patients undergoing KRT, the total energy provision by additional calories given in the form of citrate, lactate, and glucose from dialysis/hemofiltration solutions should be included in the calculations to determine the total daily energy provision to avoid overfeeding." Grade of recommendation B – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)
  • ESPEN 2021 Recommendation 4: "Intradialytic parenteral nutrition (IDPN) shall be applied in malnourished non-critically ill hospitalized patients with CKD and KF on hemodialysis, or the same patients if at risk of malnutrition that fail to respond or do not tolerate ONS or EN." Grade of recommendation A – Strong consensus (91.7% agreement). (CKD, chronic kidney disease; KF, kidney failure; ONS, oral nutritional supplements; EN, enteral nutrition.)
  • ESPEN 2021 Recommendation 27: "There is not enough evidence to support the routine use of omega-3 polyunsaturated fatty acids (PUFA) supplements or PN solutions enriched with omega-3 PUFA in hospitalized patients with AKI, AKI on CKD or CKD with KF." Grade of recommendation GPP – Strong consensus (95.8% agreement).

Bottom line

A standard central three-chamber bag with a mixed-oil lipid. In severe renal insufficiency it needs dialysis or hemofiltration access, and its 60 mmol potassium and 25 mmol phosphate per 1970 ml bag must be counted. Choose by calorie-to-protein ratio, not by brand, and monitor electrolytes closely.

Not shown here

  • Phosphate for the 493 ml and 986 ml bags (out of pattern in the fetched text; these sizes are not registered in the Philippines).

renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed

Kidney notes: SmofKabiven Peripheral

SmofKabiven Peripheral (Fresenius Kabi AB) is a lower-osmolarity three-chamber bag of amino acids with electrolytes, glucose and SMOFlipid for peripheral or central infusion. Philippine registrations: 1206, 1448 and 1904 ml bags. It is a standard formula containing potassium and phosphate.

Composition

Per presentation1206 ml bag1448 ml bag1904 ml bagper 1000 ml
Amino acids (g)38466032
Nitrogen (g)6.27.49.85.1
Lipid (g)34415428
Glucose (g)8510313571
Energy, total (kcal)80010001300700
Energy, non-protein (kcal)7008001100600
Sodium (mmol)30364825
Potassium (mmol)23283619
Magnesium (mmol)3.84.663.2
Calcium (mmol)1.92.331.6
Phosphate (mmol)9.911.915.68.2
Zinc (mmol)0.030.030.050.02
Sulfate (mmol)3.84.66.13.2
Chloride (mmol)27324222
Acetate (mmol)799612566
  • Osmolality approximately 950 mosmol/kg water; osmolarity approximately 850 mosmol/l (SmPC section 3).
  • Phosphate: contribution from both the lipid emulsion and the amino acid solution (SmPC section 2, footnote).
  • Composition from the Irish (EU) SmPC; the Philippine package insert was not available to compare.

Composition from the cited manufacturer SmPC/package insert; values independently re-checked November 17, 2026.

Dose and rate limits

  • Infusion rate should not exceed 3.0 ml/kg body weight per hour; maximum daily dose 40 ml/kg body weight per day (SmPC 4.2).

Kidney notes

  • Contraindicated in "severe renal insufficiency without access to hemofiltration or dialysis" and with pathologically elevated serum levels of any of the included electrolytes (SmPC 4.3).
  • In patients with renal insufficiency, phosphate and potassium intake should be carefully controlled to prevent hyperphosphatemia and hyperkalemia (SmPC 4.4).
  • Give with caution in impaired lipid metabolism, which may occur in renal failure, and to patients with a tendency towards electrolyte retention; correct fluid and electrolyte disturbances before starting (SmPC 4.4).
  • The lipid emulsion (SMOFlipid) contains fish oil; see ESPEN Recommendation 27 on omega-3-enriched PN in kidney disease.

How it fits the ESPEN 2021 kidney nutrition guideline

  • ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
  • ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)
  • ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
  • ESPEN 2021 Recommendation 26: "In selected patients with electrolyte and fluid imbalances, concentrated “renal” EN or PN formulas with lower electrolyte content may be preferred over standard formulas." Grade of recommendation GPP – Strong consensus (95.7% agreement). (GPP, good practice point.)
  • ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 29: "Serum glucose levels shall be maintained between 140–180 mg/dl in hospitalized patients with AKI, AKI on CKD, or CKD with KF." Grade of recommendation A – Strong consensus (95.5% agreement). Recommendation 30: "Tight glucose control (80–110 mg/dl) shall not be pursued because of the increased risk of hypoglycemia." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 14: "For patients undergoing KRT, the total energy provision by additional calories given in the form of citrate, lactate, and glucose from dialysis/hemofiltration solutions should be included in the calculations to determine the total daily energy provision to avoid overfeeding." Grade of recommendation B – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)
  • ESPEN 2021 Recommendation 4: "Intradialytic parenteral nutrition (IDPN) shall be applied in malnourished non-critically ill hospitalized patients with CKD and KF on hemodialysis, or the same patients if at risk of malnutrition that fail to respond or do not tolerate ONS or EN." Grade of recommendation A – Strong consensus (91.7% agreement). (CKD, chronic kidney disease; KF, kidney failure; ONS, oral nutritional supplements; EN, enteral nutrition.)
  • ESPEN 2021 Recommendation 27: "There is not enough evidence to support the routine use of omega-3 polyunsaturated fatty acids (PUFA) supplements or PN solutions enriched with omega-3 PUFA in hospitalized patients with AKI, AKI on CKD or CKD with KF." Grade of recommendation GPP – Strong consensus (95.8% agreement).

Bottom line

A standard peripheral three-chamber bag with a mixed-oil lipid. In severe renal insufficiency it needs dialysis or hemofiltration access; count its potassium and phosphate and its volume, and monitor electrolytes closely.

renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed

Dosage forms

Philippines

  • Emulsion for i.v. infusion
  • Emulsion for iv infusion
  • Emulsion for intravenous infusion

Registered products in the Philippines

5 products registered with the Food and Drug Administration (FDA) Philippines list Amino acids + Electrolytes + Glucose + Lipid emulsion as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Lipid Emulsion + Amino Acid + Electrolytes + Glucose (1 product) · Glucose + Amino Acids + Electrolytes + Lipid (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products5
Philippine FDA-registered products for Amino acids + Electrolytes + Glucose + Lipid emulsion
Package insert
Combiflex Lipid CentralLipid Emulsion + Amino Acid + Electrolytes + GlucoseVariant spelling
Emulsion for Intravenous Infusion (IV)1,540 mL Polypropylene 3‐Chamber Bag in Plastic Overpouch (Box of 4's); 2,053 mL Polypropylene 3‐Chamber Bag in Plastic Overpouch (Box of 2's)
Rx
JW Life Science CorporationKorea
UNILAB, Inc.
DR-XY43759
Sep 26, 2029
Combiflex Lipid PeriLipid Emulsion + Amino Acids + Electrolytes + Glucose
Emulsion for I.V. Infusion1,440 mL Polypropylene 3-Chamber Bag in Plastic Overpouch (Box of 4's); 1,920 mL Polypropylene 3-Chamber Bag in Plastic Overpouch (Box of 2's); 384 mL Polypropylene 3-Chamber Bag in Plastic Overpouch (Box of 8's)
Rx
JW Life Science CorporationRepublic of Korea
UNILAB, Inc.
DR-XY43760
Feb 20, 2032
Combiflex MCT PeriLipid Emulsion + Amino Acids + Electrolytes + Glucose
(see reverse for formulation) Emulsion for I.V. Infusion375 mL Polypropylene 3-Chamber Bag in Plastic Overpouch (Box of 8's)
Rx
JW Life Science CorporationRepublic of Korea
UNILAB, Inc.
DR-XY45790
Feb 20, 2032
Smofkabiven CentralGlucose + Amino Acids + Electrolytes + Lipid Emulsion
Emulsion for IV InfusionBiofine three-chamber bag x 1970 mL (Box of 4's)
Rx
Fresenius Kabi ABSweden
FRESENIUS KABI PHILIPPINES INC.
DR-XY40843
Dec 12, 2028
Smofkabiven PeripheralGlucose + Amino Acids + Electrolytes + LipidVariant spelling
Emulsion for IV Infusion (See reverse for formulation)Biofine three-chamber bag (1206 mL in box of 4's; 1448 mL in box of 4's; 1904 mL in box of 4's); Biofine three-chamber bag (1206 mL in box of 1's; 1448 mL in box of 1's; 1904 mL in box of 1's)
Rx
Fresenius Kabi ABSweden
Importer: Fresenius Kabi Philippines, Inc.
DR-XY40842
Apr 6, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  2. Fresenius Kabi. (2019). SmofKabiven Central emulsion for infusion, Excel bags (PA2059/058/001) [Summary of product characteristics; text revised October 2019]. Health Products Regulatory Authority. https://assets.hpra.ie/products/Human/18446/Licence_PA2059-058-001_08012020093323.pdf
  3. Fiaccadori, E., Sabatino, A., Barazzoni, R., Carrero, J. J., Cupisti, A., De Waele, E., Jonckheer, J., Singer, P., & Cuerda, C. (2021). ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. Clinical Nutrition, 40(4), 1644–1668. https://doi.org/10.1016/j.clnu.2021.01.028
  4. Fresenius Kabi. (2023). SmofKabiven Peripheral emulsion for infusion (PA2059/061/002) [Summary of product characteristics; text revised August 2023]. Health Products Regulatory Authority. https://assets.hpra.ie/products/Human/18457/Licence_PA2059-061-002_21082023121723.pdf

renalcarematters.com content: Parenteral nutrition kidney notes (SmofKabiven Central): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Parenteral nutrition kidney notes (SmofKabiven Peripheral): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .